Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

This Test Shines A Spotlight On Spreading Prostate Cancer


Developments to Watch

THIS TEST SHINES A SPOTLIGHT ON SPREADING PROSTATE CANCER

Computer tomography and magnetic resonance imaging often fail to detect the spread of prostate cancer. That leads to unnecessary surgery, because once the cancer has spread beyond the prostate, the otherwise effective treatment of surgically removing the gland has little benefit and causes undue stress. After metastasis, other measures are required, such as radiation treatment.

Now, scientists at Columbia-Presbyterian Medical Center in New York have developed the first blood test that can detect the metastasis of prostate tumors. An existing blood test, called PSA, can screen for prostate cancer--but not its location. The new test, dubbed RT-PCR, detects prostate cells in the blood--a sure sign that the cancer has spread. Aaron E. Katz, assistant professor of urology, says the test is at least 80% accurate, while MRI and CT fare no better than 60%. Abbott Laboratories and several other drug companies are interested in commercializing the method.EDITED BY OTIS PORT


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus